Assessment Of Statin Utilization Pattern For Primary Prevention In Patients With Type 2 Dm Who Have Follow Up At Diabetic Clinic In Tikur Anbessa Specialized Hospital A Hospital-based Cross Sectional Study 2021
Background: cardiovascular disease is the leading cause of morbidity and mortality among typern2 diabetic (T2DM) patients. Statin therapy is effective in reducing cardiovascular events for bothrnprimary and secondary prevention of ASCVD. rn rnObjective: to assess statin utilization extent for primary prevention of CVD in patients with typern2 DM who are above 40yrs having follow up at diabetic clinic TASH. rnMethods and materials: a hospital based cross-sectional study was conducted based on datarncollected using structured questionnaire by face-to-face interview and the digital record systemrnfrom june 10, 2021, to September 20,2021.Data entry was made using Epi info version 3.1 andrnwas analyzed using SPSS software version 25. rnRESULT: A total of 376 of patients with the age above of 40 with T2DM were participated inrnthis study. statin prescription rate was 87.4%. almost all of patients (99.1%) who are taking rnstatin were on moderate intensity and above with 59.3%% and 39.8%% received moderate andrnhigh -intensity statin respectively. From the study conducted, the most commonly prescribedrnstatin was Atorvastatin (85.6%). Predictors of statin prescription were age, use of Both insulinrnand metformin, occupational status and monthly income as independent determinants of statinrnuse. Use of both insulin and metformin increased the odds of statin use by 2.29 times asrncompared to the counterparts [AOR= 2.29; 95% CI: 1.07, 4.95]. Having other occupation led torn79% less odds for statin use as compared to government employees [AOR=0.21; 95% CI: 0.09,rn0.51]. For each 1-year increase in the age of the patients, the odds of using statin increases by 5%rn[AOR= 1.05; 95% CI: 1.02, 1.10]. rnCONCLUSION: In conclusion this study done at showed the highest rate of statin prescriptionrnof 87% for primary prevention of ASCVD in type 2 DM patients who are above 40 compared tornother studies done recently.Which is consistent with contemporary guidelines recommendationrnfor dyslipidemia and primary prevention of ASCVD.